世界肾脏病大会（WCN）暨第21届亚太肾脏病学会大会（APCN）将于2023年3月30日至4月2日在泰国曼谷举行。本次大会总计收集了1200篇以上的poster和abstract，研究内容主要集中在慢性肾脏病（CKD）、免疫球蛋白A（IgA）肾病、急性肾损伤（AKI）等方面。
IgA肾病的研究进展
1.IgA肾病患者尿液mi-RNA的特征——一项临床观察性病例-对照研究
URINARYEXOSOMAL MIRNA SIGNATURE OF PATIENTS WITH IGA NEPHROPATHY - A CLINICALOBSERVATIONAL CASE - CONTROL STUDY
摘要号：WCN23-0087
2. 通过外周血转录组分析鉴定IgA肾病的关键生物标志物和免疫细胞浸润
IDENTIFICATIONOF KEY BIOMARKERS AND IMMUNE CELL INFILTRATION IN IGA NEPHROPATHY BY PERIPHERALBLOOD TRANSCRIPTOME ANALYSIS
摘要号：WCN23-0771
3. SGLT-2抑制剂治疗对IgA肾病患者蛋白尿的影响
THEEFFECT OF SGLT2 INHIBITORS TREATMENT ON PROTEINURIA IN PATIENTS WITH IGANEPHROPATHY
摘要号：WCN23-0052
4. IPTACOPAN对IgA肾病患者随时间推移的蛋白尿和补体生物标志物的影响
EFFECTOF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgANEPHROPATHY
摘要号：WCN23-0412
5.口服低剂量甲泼尼龙在IgA肾病中的疗效和安全性:Testing 研究
EFFICACYAND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THETESTING TRIAL
摘要号：WCN23-0069
6.系统性菌群失调与IgA肾病相关
SYSTEMATICMICROBIOME DYSBIOSIS ARE ASSOCIATED WITH IGA NEPHROPATHY
摘要号：WCN23-0905
CKD的药物治疗进展
1.肾内科CKD患者多药治疗及药物相互作用分析
ANALYSISOF POLYPHARMACY AND DRUG INTERACTIONS PRESCRIBED TO PATIENTS WITH CHRONIC KIDNEYDISEASES IN NEPHROLOGY DEPARTMENT
摘要号：WCN23-0580
2. CKD患者长期使用RAAS阻断剂后出现无法解释的急性肾损伤，停用药物四年内的肾脏和死亡结果：POST STOP ACEI研究。
FOUR-YEARRENAL AND MORTALITY OUTCOMES AFTER STOPPING LONG-TERM RAAS BLOCKADE IN CKDPATIENTS WITH OTHERWISE INEXPLICABLE PROGRESSIVE NEW-ONSET ACUTE-KIDNEY-INJURY:A POST STOP ACEi TRIAL REVIEW
摘要号：WCN23-1002
3. 卡格列净对非糖尿病肥胖伴白蛋白尿患者的影响:一项随机、双盲、安慰剂对照试验
EFFECTOF CANAGLIFLOZIN IN NON-DIABETIC OBESE PATIENTS WITH ALBUMINURIA: A RANDOMIZED,DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
摘要号：WCN23-0397
4.高血浆草酸促进1-3期CKD患者的慢性炎症
ELEVATEDPLASMA OXALIC ACID PROMOTES CHRONIC INFLAMMATION IN STAGE 1-3 CKD PATIENTS
摘要号：WCN23-0701
AKI的诊疗进展
1. 肾脏尿素和尿酸排泄分数对区分急性肾损伤和慢性肾脏病具有诊断价值
RENALFRACTIONAL EXCRETION OF UREA AND URIC ACID HAVE A DIAGNOSTIC VALUE TODISTINGUISH ACUTE KIDNEY INJURY FROM CHRONIC KIDNEY DISEASE
摘要号：WCN23-0173
2. 维生素b复合物在急性肾损伤患者中的应用:VIBAKI研究
VITAMINB COMPLEX IN PATIENTS WITH ACUTE KIDNEY INJURY THE VIBAKI TRIAL
摘要号：WCN23-0889
3. AKI危重症患者的红细胞分布宽度（RDW）和中性粒细胞淋巴细胞比率（NLR）与预后结局的关系
ASSOCIATIONOF RED CELL DISTRIBUTION WIDTH (RDW) AND NEUTROPHIL LYMPHOCYTE RATIO (NLR) WITHOUTCOMES AMONG PATIENTS WITH ACUTE KIDNEY INJURY (AKI) IN CRITICAL CARE SETTING
摘要号：WCN23-0418
其他研究亮点
1.SPARSENTAN对年轻局灶节段性肾小球硬化（FSGS）患者的长期疗效和安全性:DUTE研究的开放标签扩展分析-240周分析（OLE）
LONG-TERMEFFICACY AND SAFETY OF SPARSENTAN IN YOUNG PATIENTS WITH FSGS: 240-WEEKANALYSIS OF THE DUET OPEN-LABEL EXTENSION (OLE)
摘要号：WCN23-1184
2. 青蒿琥酯治疗活动性狼疮性肾炎的随机、双盲、对照试验
RANDOMIZED,DOUBLE-BLIND, CONTROLLED TRIAL OF ARTESUNATE IN PATIENTS WITH ACTIVE LUPUSNEPHRITIS
摘要号：WCN23-1043
3. 将高钾水果纳入血液透析患者饮食中的安全性和有效性
SAFETYAND EFFICACY OF INCORPORATING HIGH POTASSIUM FRUITS IN THE DIET OF HEMODIALYSISPATIENTS
摘要号：WCN23-0778
4. 一项评价LNP023（Iptacopan）治疗c3肾小球疾病的长期疗效、安全性和耐受性的开放标签、非随机扩展研究:2期研究的中期分析
ANOPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE LONG-TERM EFFICACY,SAFETY, AND TOLERABILITY OF LNP023 IN SUBJECTS WITH C3 GLOMERULOPATHY: INTERIMANALYSIS OF PHASE 2 STUDY
摘要号：WCN23-0403
5. 钙调神经磷酸酶抑制剂与环磷酰胺治疗原发性膜性肾病患者的预后:一项多中心、真实世界的回顾性研究
THEPROGNOSIS OF PATIENTS WITH PRIMARYMEMBRANOUS NEPHROPATHY TREATEDWITHCALCINEURIN INHIBITORS VS.CYCLOPHOSPHAMIDE: A MULTI-CENTER, REAL-WORLD,RETROSPECTIVE STUDY
摘要号：WCN23-1047
6. 利妥昔单抗治疗原发性膜性肾病的临床证据
RITUXIMABTHERAPY FOR PRIMARY MEMBRANOUS NEPHROPATHY : A CLINICAL EVIDENCE
摘要号：WCN23-0844
总的来说，来自世界各国的学者、专家将齐聚WCN 23，共同讨论肾病与肾脏健康。医脉通将在3月30日至4月7日期间连续报道WCN 23，为大家带来最新的前沿资讯！
参考文献：
1.WCNeposter. Kidney International Reports. Mar 20,2022.